Physician profile
Lora M Cooper-Yoakum
NPI 1689092751
$18,077.21
in general payments reported to CMS, 2019-2025
36 companies · $4,706 in 2025
The $4,706 reported for 2025 was more than what 99% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,618 · 2022: $3,807 · 2023: $3,374 · 2024: $4,573 · 2025: $4,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $736 · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,574.24 |
| Consulting Fee | $736.00 |
| Education | $341.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,940.91 | 2021-2025 | |
| Amgen INC. | $3,537.96 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $1,648.43 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $1,126.26 | 2021-2025 | Saphnelo, Evusheld |
| E.R. Squibb & Sons, L.L.C. | $1,066.30 | 2021-2025 | Orencia |
| Glaxosmithkline, LLC. | $836.18 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $830.79 | 2021-2025 | Taltz, Zepbound |
| Janssen Biotech, INC. | $830.42 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Genzyme Corporation | $619.56 | 2021-2025 | |
| Horizon Therapeutics Plc | $495.76 | 2022-2023 | Krystexxa |
| Pfizer INC. | $338.40 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.66 | 2022-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $301.68 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $293.46 | 2021-2025 | Acthar |
| Radius Health, INC. | $270.59 | 2021-2025 | Tymlos |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $178.99 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $172.73 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $140.58 | 2022-2025 | Strensiq, Ultomiris |
| Organon LLC | $128.16 | 2022-2025 | Hadlima, Renflexis |
| Novo Nordisk INC | $121.91 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $104.55 | 2024 | Arcalyst |
| Sobi, INC | $100.13 | 2021-2024 | |
| Fresenius Kabi USA, LLC | $96.23 | 2023-2024 | Idacio |
| Sandoz INC. | $94.27 | 2024-2025 | Hyrimoz |
| Genentech USA, INC. | $57.87 | 2023-2025 | Actemra |
| Takeda Pharmaceuticals U.S.A., INC. | $55.45 | 2022-2024 | Hyqvia, Cuvitru |
| Scilex Pharmaceuticals INC. | $52.92 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $47.79 | 2023-2024 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $45.47 | 2021-2023 | Mitigare |
| Teva Pharmaceuticals USA, INC. | $40.96 | 2022-2024 | Truxima, Simlandi |
| Boston Scientific Corporation | $39.18 | 2023 | Superion Indirect Decompression System |
| Kyowa Kirin, INC. | $34.14 | 2024 | Crysvita |
| Kiniksa Pharmaceuticals, Ltd. | $26.20 | 2023 | Arcalyst |
| Acadia Pharmaceuticals INC | $25.28 | 2021 | |
| Tersera Therapeutics LLC | $24.09 | 2025 | Quzyttir |
| Celltrion USA INC. | $15.95 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Cooper-Yoakum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.